These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 6304480

  • 21. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus.
    Mathes LE, Olsen RG, Hebebrand LC, Hoover EA, Schaller JP, Adams PW, Nichols WS.
    Cancer Res; 1979 Mar; 39(3):950-5. PubMed ID: 218725
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Abrogation of resistance to feline oncornavirus disease by immunization with killed feline leukemia virus.
    Olsen RG, Hoover EA, Schaller JP, Mathes LE, Wolff LH.
    Cancer Res; 1977 Jul; 37(7 Pt 1):2082-5. PubMed ID: 67886
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukaemia virus glycoprotein sequence.
    Nick S, Klaws J, Friebel K, Birr C, Hunsmann G, Bayer H.
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():77-83. PubMed ID: 1689371
    [Abstract] [Full Text] [Related]

  • 26. Influence of antisera to oncornavirus glycoprotein (gp71) on infections of cats with feline leukemia virus.
    de Noronha F, Schäfer W, Essex M, Bolognesi DP.
    Virology; 1978 Apr; 85(2):617-21. PubMed ID: 208242
    [No Abstract] [Full Text] [Related]

  • 27. Endogenous RD-114 virus of cats: absence of antibodies to RD-114 envelope antigens in cats naturally exposed to feline leukemia virus.
    Mandel MP, Stephenson JR, Hardy WD, Essex M.
    Infect Immun; 1979 Apr; 24(1):282-5. PubMed ID: 222681
    [Abstract] [Full Text] [Related]

  • 28. Circulating antibodies to the feline leukemia virus and FOCMA in cats.
    Lizonová A, Grófová M.
    Neoplasma; 1983 Apr; 30(3):281-6. PubMed ID: 6306490
    [Abstract] [Full Text] [Related]

  • 29. Vaccination against feline leukaemia virus using a cell membrane antigen system.
    Jarrett W, Jarrett O, Mackey L, Laird H, Hood C, Hay D.
    Int J Cancer; 1975 Jul 15; 16(1):134-41. PubMed ID: 170211
    [Abstract] [Full Text] [Related]

  • 30. Influence of antibody infusion on pathogenesis of experimental feline leukemia virus infection.
    Haley PJ, Hoover EA, Quackenbush SL, Gasper PW, Macy DW.
    J Natl Cancer Inst; 1985 Apr 15; 74(4):821-7. PubMed ID: 2985857
    [Abstract] [Full Text] [Related]

  • 31. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
    Lehmann R, von Beust B, Niederer E, Condrau MA, Fierz W, Aubert A, Ackley CD, Cooper MD, Tompkins MB, Lutz H.
    Vet Immunol Immunopathol; 1992 Dec 15; 35(1-2):199-214. PubMed ID: 1363009
    [Abstract] [Full Text] [Related]

  • 32. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge.
    Langhammer S, Hübner J, Jarrett O, Kurth R, Denner J.
    Antiviral Res; 2011 Jan 15; 89(1):119-23. PubMed ID: 21108970
    [Abstract] [Full Text] [Related]

  • 33. Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated.
    Hoover EA, Schaller JP, Mathes LE, Olsen RG.
    Infect Immun; 1977 Apr 15; 16(1):54-9. PubMed ID: 194840
    [Abstract] [Full Text] [Related]

  • 34. [Feline leukemogenic and sarcomatogenic viruses].
    Parodi AL.
    C R Seances Soc Biol Fil; 1975 Apr 15; 169(3 Suppl):794-806. PubMed ID: 175893
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of an inactivated feline leukemia virus vaccine.
    Hoover EA, Mullins JI, Chu HJ, Wasmoen TL.
    AIDS Res Hum Retroviruses; 1996 Mar 20; 12(5):379-83. PubMed ID: 8882314
    [Abstract] [Full Text] [Related]

  • 36. Anti-idiotypic antibodies to feline leukemia virus: an approach for retroviral immunization strategies.
    Tavares L, Roneker C, Postie L, Fevereiro M, de Noronha F.
    Viral Immunol; 1991 Mar 20; 4(1):5-16. PubMed ID: 1648360
    [Abstract] [Full Text] [Related]

  • 37. Subunit vaccines against exogenous retroviruses: overview and perspectives.
    Hunsmann G.
    Cancer Res; 1985 Sep 20; 45(9 Suppl):4691s-4693s. PubMed ID: 2410114
    [Abstract] [Full Text] [Related]

  • 38. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.
    Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M.
    Clin Vaccine Immunol; 2015 Jul 20; 22(7):798-805. PubMed ID: 25972402
    [Abstract] [Full Text] [Related]

  • 39. Feline leukemia virus-and feline sarcoma virus-related polypeptides released by virus producer and nonproducer cells.
    Ganguly K, Essex M.
    Cancer Invest; 1985 Jul 20; 3(6):523-34. PubMed ID: 3002564
    [Abstract] [Full Text] [Related]

  • 40. Polypeptides of feline leukaemia virus: identification of p15(E) and p12(E).
    Neil JC, Onions DE, Jarrett O.
    J Gen Virol; 1980 Oct 20; 50(2):455-60. PubMed ID: 6257828
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.